|
مقاله
|
Abstract
|
|
|
Title:
|
Topical Interferon Alpha 2b in the Treatment of Vernal Keratoconjunctivitis
|
Author(s):
|
Habibollah Zanjani MD; Alireza Maleki MD; Abdolhossein Ghafourian MD; Mojtaba Abrishami MD
|
Presentation Type:
|
Oral
|
Subject:
|
Cornea and Anterior Segment
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Habibollah Zanjani
|
Affiliation :(optional)
|
alzahra eye hospital - zahedan
|
E mail:
|
zanjanih@zaums.ac.ir
|
Phone:
|
3224991
|
Mobile:
|
09115410911
|
|
|
Purpose:
|
To evaluate the efficacy and safety of a 2-month topical interferon alpha 2b (IFN-α2b) treatment in patients with moderate to severe and refractory vernal keratoconjunctivitis (VKC).
|
Methods:
|
In an observational case series study, 15 individuals (12 males, 3 females), 6 to 25 years having bilateral VKC were included. Exclusion criteria were history of any intraocular or corneal disease, anomaly or surgery. Patients received topical treatment with one million IU/mL interferon alpha 2b, 4 times a day for 2 months. Each patient was evaluated at before and 2, 4, 6 and 8 weeks after the treatment initiation. Subjective and objective scores were evaluated at the baseline and at the follow ups. Descriptive analysis and paired-samples t test were used for statistical analysis.
|
Results:
|
No significant complications or side effects associated with the use of topical interferon alpha 2b were observed. Symptom scores for itching, tearing, photophobia, redness, foreign body sensation and total symptom score for corneal lesions, papillary hypertrophy, limbal hyperemia, limbal hypertrophy, corneal PEE, and total examination score significantly improved during the 2-month treatment.
|
Conclusion:
|
Administration of topical IFN-α2b alleviated VKC symptoms and signs. IFN-α2b can be recommended as an effective and safe therapy for moderate to severe and refractory VKC.
|
Attachment:
|
|
|